Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Date:1/4/2008

SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc. announced today that Matthew J. Meyer has been named General Counsel, a newly established position, and Vice President of Business Development and Licensing. Mr. Meyer is a global life sciences executive and corporate attorney with broad experience with large pharmaceutical, medical device and early-stage companies in the US and Europe. In the business development role, he replaces Timothy J. McBride, who will be furthering his career in Europe. Mr. Meyer will report to Paul Sekhri, President and CEO, and will be responsible for managing the Company's efforts to identify and secure new strategic business opportunities and product acquisitions.

Mr. Meyer brings considerable experience to his new role in the areas of commercial law, business development, marketing and licensing. Before joining Cerimon, Mr. Meyer held senior management positions at Draeger Medical Systems, a global medical device company, most recently serving as Vice President and General Counsel. Prior to Draeger, Mr. Meyer held several positions of increasing responsibility at Novartis Pharma AG in Basel, Switzerland, including serving as Head of Global Marketing Channel Innovations. While at Novartis, he also coordinated and implemented strategic commercial, marketing, research and development initiatives for the Arthritis, Bone, GI and Urology (ABGU) marketing franchise. Previously, Mr. Meyer spent four years as Vice President, Global Business Development and Legal Affairs at Allscripts LLC and five years as a commercial attorney at Pfizer Inc. in New York.

Mr. Meyer graduated Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Cornell University. He earned his Juris Doctor degree from Villanova University School of Law.

"Matt Meyer's proven track record as an incisive leader in business development in the life sciences sector will be a valuable asset to this Company," comment
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... 5 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:,SDI) today ... Toray,Medical Co. Ltd. for the marketing and sale ... cleared assay for the measurement of,endotoxin. Under the ... access to Toray,s distributors in new geographic territories,including ...
... with Bioscene in Japan - Expands Presence in Japan, ... announced,today that the Japan Patent Office (JPO) has licensed ... Inc. (Bioscene) as,its exclusive partner for the distribution of ... assist the JPO in the review and approval,of patent ...
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... AeroLEF(TM) will be presented at The 27th Annual,Scientific ... place May,8-10, 2008 in Tampa, Florida., The ...
Cached Biology Technology:Spectral and Toray expand collaboration to include new geographic territories 2Spectral and Toray expand collaboration to include new geographic territories 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 2Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 4YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING 2
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... suffered a stroke continued to experience eating problems and more than ... been a marked improvement in most of their physical functions. That ... March issue of the Journal of Advanced Nursing . ... who had had a stroke, assessing them in hospital at a ...
... Collaborative research from the WALTHAM Centre for Pet Nutrition ... who own dogs are more physically active than those who ... women who owned dogs were approximately 50% more likely to ... assessed over 11,000 pregnant women in the UK using data ...
... In a coup for a university without a medical ... received prestigious 2012 Sloan Research Fellowships from the Alfred ... Meyer, Assistant Professor of Physics Ying Ran, Assistant Professor ... Liane Young were among the 126 researchers recognized by ...
Cached Biology News:Eating problems persist 3 months after stroke and 56 percent still face malnutrition risk 2Dog owners more likely to achieve recommended activity levels during pregnancy 24 Boston College faculty members named Sloan Research Fellows 24 Boston College faculty members named Sloan Research Fellows 3
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
... in immunostaining ,This solution has effect on ... get clearer signal than the one obtained ... amount of secondary antibody used and exposure ... can have images with high S/N ratio ...
Biology Products: